Investing in the Future of Precision Gene and RNA Therapies
Partner with Dawn Therapeutics to accelerate the development of targeted treatments for CNS, lysosomal storage, and musculoskeletal disorders
Why Invest in Dawn Therapeutics?
Dawn Therapeutics is a science-driven, patient-focused biotech with a mission to deliver next-generation gene and RNA medicines precisely where they are needed.
Our investment proposition:
- Proprietary Tissue-Targeted Delivery Platforms – Unique AAV and LNP systems optimised for CNS, cartilage, muscle, and liver delivery.
- Diversified Pipeline – 21 therapeutic programmes across CNS, lysosomal storage diseases, and musculoskeletal disorders.
- Strong IP Portfolio – Broad patent protection covering delivery systems, manufacturing methods, and therapeutic programmes.
- Global Partnerships – Collaborations with academic leaders, industry partners, and patient advocacy groups.
Scalable Manufacturing – GMP-ready processes to enable rapid progression from clinical trials to commercial supply
Our Strategic Focus
We operate at the intersection of innovation, unmet need, and market opportunity:
Unmet Need
Rare and complex diseases with no effective treatment options.
Innovation
Proprietary delivery platforms enabling unprecedented tissue specificity.
Market Opportunity
Multi-billion-dollar addressable markets in CNS and rare genetic diseases.
Our Strategic Focus
Our therapeutic pipeline is strategically diversified to balance
Our therapeutic pipeline is strategically diversified to balance
Platform leverage (multiple diseases addressed with a single delivery technology).
Balanced risk profile (mix of early and mid-stage assets).
Recent Highlights
Initiated preclinical studies in MPS I & II gene therapy programmes.
Expanded CNS portfolio to include targeted mRNA therapy for Autism Spectrum Disorder.
Filed key patents securing global rights to new AAV capsid designs.
Established scalable GMP manufacturing partnerships.
Investment Opportunities
We welcome
Equity Investment
Support our clinical development and global expansion.
Strategic Partnerships
Co-develop therapies in selected disease areas.
Licensing Deals
Access our delivery platforms for your programmes
Grant & Consortium Funding
Collaborate on translational and global health projects.
Financial Governance
Operate under stringent corporate governance aligned with biotech best practices.
Maintain transparent financial reporting and milestone-based investor updates.
Protect shareholder value with disciplined capital allocation.